Aural Analytics develops non-invasive speech analysis technology designed to assess neurological health and support monitoring of neurodegenerative diseases. The company’s platform focuses on extracting clinically relevant information from natural speech to provide objective measures of brain function. Its software-based approach enables remote and repeatable assessments without the need for specialized hardware. The system is intended for use in clinical and research settings.

The technology analyzes acoustic, linguistic, and temporal features of speech that correlate with neurological and cognitive function. By applying signal processing and machine learning methods, the platform identifies patterns associated with disease progression or treatment response. These speech-derived biomarkers can be collected longitudinally, enabling continuous monitoring over time. The approach emphasizes scalability and low patient burden compared to traditional neurological assessments.

Aural Analytics positions its solution for use in clinical trials, disease monitoring, and neurological research, particularly in conditions such as Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders. The platform is designed to integrate into regulated clinical workflows and digital health infrastructures. Its focus on speech as a biomarker reflects growing interest in passive, non-invasive measures for tracking neurological health.